Latest AI and machine learning research in skin cancer for healthcare professionals.
Discriminative classifiers have become a foundational tool in deep learning for medical imaging, excelling at learning separable features of complex data distributions. However, these models often need careful design, augmentation, and training techniques to ensure safe and reliable deployment. Recently, diffusion models have become synonymous with generative modeling in 2D. These models showcas...
IMPORTANCE: Only a small fraction of patients with advanced non-small cell lung cancer (NSCLC) respond to immune checkpoint inhibitor (ICI) treatment. For optimal personalized NSCLC care, it is imperative to identify patients who are most likely to benefit from immunotherapy.
Medical research, driven by advancing technologies like artificial intelligence (AI), is transforming healthcare. Dermatology, known for its visual na...
The level of tumour-infiltrating lymphocytes (TILs) is a prognostic factor for patients with (triple-negative) breast cancer (BC). Computational TIL...
Given multi-type point maps from different place-types (e.g., tumor regions), our objective is to develop a classifier trained on the source place-t...
Melanoma is characterized by its rapid progression and high mortality rates, making early and accurate detection essential for improving patient outco...
Artificial intelligence (AI) is significantly advancing precision medicine, particularly in the fields of immunogenomics, radiomics, and pathomics. In...
Multiplex immunofluorescence (mIF) imaging plays a crucial role in studying multiple biomarkers and their interactions within the tumour microenvironm...
We introduce HLAIIPred, a deep learning model to predict peptides presented by class II human leukocyte antigens (HLAII) on the surface of antigen pre...
Tissue microenvironments reprogram local cellular states in disease, yet current computational spatial methods remain descriptive and do not simulate ...
The tumor microenvironment (TME) is a complex ecosystem of diverse cell types whose interactions govern tumor growth and clinical outcome. While multi...
Despite its potential in cancer therapy, single-atom nanozyme (SAzyme) faces challenges like low atomic loading and rapid cancer metabolism. Here, a h...
Despite improved outcomes with atezolizumab plus bevacizumab (A+B) in hepatocellular carcinoma (HCC), primary refractoriness (PRef), characterised by ...
The immune system is an intricately evolved series of cellular and protein-protein interactions, which defend the body against pathogens and abnormal ...
The development of personalized cancer vaccines relies heavily on accurately identifying neoepitopes capable of eliciting strong immune responses. T c...
Chimeric antigen receptor (CAR) T cell therapy holds transformative potential for hematologic malignancies, yet predicting patient-specific treatment ...
Elucidating drug response mechanisms in human melanoma is crucial for improving treatment outcomes. Although scRNA-seq captures gene expression at the...
Identifying effective neoantigen sequences is essential for enhancing anti-tumor immunity. However, the vast sequence space (>109 possible peptides) a...
Human haematopoietic stem and progenitor cells (HSPCs) exhibit heterogeneous lineage output, but the molecular programs underlying clonal fate remain ...
Deep learning shows promise in structure-based drug discovery, yet challenges persist in generating pharmacologically plausible molecules with valid 3...